Skip to content

    NEUROCRINE BIOSCIENCES (NBIX) stock price & financials

    View NBIX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+11.5% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $622.10M
    $627.70M
    $572.60M
    $687.50M
    $794.90M
    +27.8%
    $805.50M
    +28.3%
    $814.50M
    +42.2%
    $959.00M
    +39.5%
    Strengthening
    Operating Profit
    $183.80M
    $142.00M
    $23.60M
    $145.60M
    $239.00M
    +30.0%
    $210.90M
    +48.5%
    $193.40M
    +719.5%
    $151.50M
    +4.1%
    Strengthening
    Net Profit
    $129.80M
    $103.10M
    $7.90M
    $107.50M
    $209.50M
    +61.4%
    $153.70M
    +49.1%
    $197.90M
    +2405.1%
    $144.40M
    +34.3%
    Strengthening
    EPS
    $1.28
    $0.08
    $1.09
    $2.11
    +64.8%
    $1.97
    +2362.5%
    $1.43
    +31.2%
    Strengthening
    Other Income
    $6.50M
    $20.60M
    -$8.90M
    $13.90M
    $52.80M
    +712.3%
    $28.50M
    +38.3%
    $53.40M
    $10.70M
    -23.0%
    Strengthening
    Interest
    $0
    $2.90M
    Depreciation
    Profit before Tax
    $190.30M
    $162.60M
    $14.70M
    $159.50M
    $291.80M
    +53.3%
    $239.40M
    +47.2%
    $246.80M
    +1578.9%
    $162.20M
    +1.7%
    Strengthening
    MarginsOPM
    29.6%
    22.6%
    4.1%
    21.2%
    30.1%
    +1.8%
    26.2%
    +15.7%
    23.7%
    +476.2%
    15.8%
    -25.4%
    Strengthening
    Tax
    31.8%
    36.6%
    46.3%
    32.6%
    28.2%
    -11.3%
    35.8%
    -2.2%
    19.8%
    -57.2%
    11.0%
    -66.3%
    Weakening
    ReturnsROIC
    17.9%
    14.2%
    1.1%
    14.8%
    28.9%
    +61.4%
    21.2%
    +49.1%
    27.3%
    +2405.1%
    19.9%
    +34.3%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$141.71M$112.30M$187.10M$340.80M$262.90M$251.10M$233.00M$713.00M$332.40M
    Short-Term Investments$509.20M$558.20M$613.90M$370.50M
    Total Current Assets$737.78M$831.00M$1.02B$972.80M$1.45B$1.61B$1.72B$2.52B$1.64B
    Net PP&E$33.87M$116.20M$127.40M$155.80M$145.60M$347.30M$592.00M$545.20M$538.50M
    Goodwill$0$5.40M$5.80M$5.70M$6.10M$500.60M
    Intangibles$0$37.20M$35.50M$36.50M$4.70M$2.23B
    Total Assets$993.15M$1.31B$1.73B$2.07B$2.37B$3.25B$3.72B$4.63B$5.36B
    LiabilitiesTotal Current Liabilities$88.23M$565.30M$186.50M$245.80M$537.70M$654.80M$507.70M$743.40M$874.50M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$0$86.70M$94.40M$105.30M$93.50M$258.30M$455.10M$415.30M$401.80M
    Total Liabilities$512.39M$669.10M$608.50M$698.50M$660.90M$1.02B$1.13B$1.38B$1.67B
    EquityCommon Stock & APIC$91.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K
    Retained Earnings-$1.18B-$1.13B-$725.40M-$635.80M-$406.80M-$157.10M$29.20M$447.70M$724.00M
    Total Equity$480.80M$636.90M$1.13B$1.37B$1.71B$2.23B$2.59B$3.25B$3.69B
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$101.40M$147.00M$228.50M$256.50M$339.40M$389.90M$595.40M$782.70M$898.10M
    Cash from Investing-$242.90M-$211.10M$4.10M-$130.20M-$177.10M-$467.10M-$126.80M-$264.40M-$891.20M
    Cash from Financing$29.50M$32.40M-$157.80M$27.40M-$234.30M$65.30M-$486.70M-$38.30M$60.20M
    SummaryCapital Expenditure-$24.80M-$14.70M-$10.90M-$23.40M-$16.50M-$28.30M-$38.20M-$34.00M-$27.70M
    Free Cash Flow$76.60M$132.30M$217.60M$233.10M$322.90M$361.60M$557.20M$748.70M$870.40M
    FCF Margin17.0%16.8%20.8%20.6%21.7%19.2%23.7%26.2%25.8%

    Ratios